Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Next Previous
Trial Profile

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELVN-001 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ENABLE
  • Sponsors Enliven Therapeutics

Most Recent Events

  • 03 Nov 2025 According to an Enliven Therapeutics media release, company announced As of the cutoff date of April 28, 2025, six patients with previously treated chronic phase CML who had an atypical transcript received ELVN-001 at doses from 20 mg to 80 mg twice daily (BID) in the dose escalation phase of the ENABLE study.
  • 03 Nov 2025 Results presented in theEnliven Therapeutics Media Release.
  • 03 Nov 2025 According to an Enliven Therapeutics media release, company announced the Company will present data from the ongoing ENABLE Phase 1a/1b clinical trial of ELVN-001 on a subset of chronic myeloid leukemia (CML) patients, specifically in patients with atypical fusion transcripts, at the 67th Annual American Society of Hematology (ASH) 2025 Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top